Last reviewed · How we verify
APDC + Chemotherapy
APDC is an immunotherapeutic agent combined with chemotherapy to enhance anti-tumor immune responses and cytotoxic effects.
APDC is an immunotherapeutic agent combined with chemotherapy to enhance anti-tumor immune responses and cytotoxic effects. Used for Advanced or metastatic solid tumors (in combination with chemotherapy).
At a glance
| Generic name | APDC + Chemotherapy |
|---|---|
| Sponsor | Second Military Medical University |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
APDC (likely an immunomodulatory or checkpoint-related compound) is administered alongside standard chemotherapy regimens to potentiate both direct cytotoxic killing and immune-mediated tumor destruction. The combination approach aims to overcome chemotherapy resistance and improve overall survival by engaging both innate and adaptive immune mechanisms while maintaining chemotherapy efficacy.
Approved indications
- Advanced or metastatic solid tumors (in combination with chemotherapy)
Common side effects
- Chemotherapy-related myelosuppression
- Immune-related adverse events
- Gastrointestinal toxicity
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APDC + Chemotherapy CI brief — competitive landscape report
- APDC + Chemotherapy updates RSS · CI watch RSS
- Second Military Medical University portfolio CI